Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

NCT00352521 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: bevacizumab
DRUG: irinotecan
PROCEDURE: dynamic contrast-enhanced magnetic resonance imaging

Sponsor

Duke University

Collaborators

[object Object]